Bioverativ Inc (NASDAQ:BIVV) has been assigned a consensus recommendation of “Hold” from the thirteen analysts that are presently covering the company, Marketbeat.com reports. Eleven investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $64.20.
BIVV has been the subject of a number of recent research reports. Zacks Investment Research raised Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 target price for the company in a report on Monday, January 8th. William Blair reissued a “hold” rating on shares of Bioverativ in a report on Thursday, March 8th. Royal Bank of Canada raised their price target on Bioverativ to $68.00 and gave the company a “market perform” rating in a report on Thursday, January 18th. Jefferies Group raised their price target on Bioverativ to $79.00 and gave the company a “buy” rating in a report on Thursday, January 18th. Finally, Raymond James cut Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd.
Shares of BIVV remained flat at $$104.98 during mid-day trading on Thursday. Bioverativ has a 12 month low of $48.14 and a 12 month high of $105.01.
Bioverativ (NASDAQ:BIVV) last issued its earnings results on Tuesday, February 13th. The biotechnology company reported $0.76 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.01. Bioverativ had a return on equity of 40.99% and a net margin of 30.43%. The business had revenue of $328.70 million during the quarter, compared to analysts’ expectations of $325.89 million. research analysts predict that Bioverativ will post 3.82 EPS for the current fiscal year.
Large investors have recently bought and sold shares of the company. Robeco Institutional Asset Management B.V. bought a new position in shares of Bioverativ in the 4th quarter worth $105,000. American Assets Investment Management LLC bought a new position in shares of Bioverativ in the 4th quarter worth $108,000. Ladenburg Thalmann Financial Services Inc. bought a new position in shares of Bioverativ in the 3rd quarter worth $190,000. Bailard Inc. bought a new position in shares of Bioverativ in the 4th quarter worth $216,000. Finally, Rehmann Capital Advisory Group bought a new position in shares of Bioverativ in the 4th quarter worth $241,000. Institutional investors and hedge funds own 97.18% of the company’s stock.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.